Overview
Valrubicin is a semisynthetic anthracycline derivative developed as a less cardiotoxic alternative to doxorubicin. Approved by the FDA in 1998 (brand name Valstar), it's specifically indicated for intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder. The drug exhibits both cytotoxic and fluorescent properties, the latter being useful for visualizing treated areas during procedures. As a topoisomerase II inhibitor, valrubicin intercalates into DNA and creates cytotoxic complexes that block DNA and RNA synthesis. Its unique N-trifluoroacetyladriamycin-14-valerate structure enhances bladder tissue penetration while reducing systemic absorption compared to other anthracyclines.
Physical and Chemical Properties
Valrubicin hydrochloride appears as a red-orange lyophilized powder that forms a clear red solution when reconstituted with saline. The compound shows pH-dependent stability, being most stable in slightly acidic conditions (pH 4-5). Its fluorescence peaks at 470nm excitation/550nm emission, a property utilized in clinical monitoring. The drug's amphiphilic nature (logP ~1.5) facilitates both aqueous solubility for administration and sufficient lipophilicity for tissue penetration. In solution, it demonstrates concentration-dependent aggregation behavior that affects both pharmacological activity and stability. Degradation occurs via hydrolysis (especially at higher pH) and photooxidation, necessitating protection from light.
Main Applications
Valrubicin's primary use is as an intravesical chemotherapeutic agent for non-muscle-invasive bladder cancer (NMIBC), particularly for carcinoma in situ (CIS) that has failed BCG immunotherapy. Treatment typically involves weekly instillations for 6 weeks using 800mg doses dissolved in 55mL saline. Off-label uses include experimental applications in other localized malignancies where direct tissue access is possible. Research suggests potential in peritoneal malignancies and certain ocular tumors. The drug's fluorescence properties have also been explored for photodynamic therapy applications, though this remains investigational.
Safety and Storage
As a cytotoxic agent, valrubicin requires strict handling protocols including gloves, gowns, and eye protection. Spills should be contained with absorbent materials and cleaned with appropriate deactivation solutions. Unused portions must be disposed as hazardous pharmaceutical waste. For storage, maintain lyophilized powder at 2-8°C in original packaging. Reconstituted solutions are stable for 12 hours at room temperature or 72 hours if refrigerated (2-8°C), but should ideally be used immediately. Never freeze reconstituted solutions. Vials should be inspected for discoloration or particulate matter before use.
B2B Procurement Guide
Pharmaceutical purchasers should verify supplier GMP certification and cold chain compliance documentation. Minimum order quantities typically apply due to specialized manufacturing. Lead times of 4-8 weeks are common for non-stock items. Key procurement considerations include: batch-specific certificates of analysis, import/export licensing for controlled substances (varies by country), and validation of temperature monitoring during transport. Many institutions require vendor audits for cytotoxic drug suppliers. Contract terms should address recall procedures and liability for temperature excursions.